Kornimate/medical-research-clean huggingface dataset:
efficacy of the combination bismuth + neomycin + procaine in the treatment of recurrent aphthous ulceration

Conditions: Aphtous Ulcers

Summary: to evaluate the efficacy of the product bismu-jet ® (bismuth tartrate and sodium, neomycin sulfate and procaine hydrochloride) produced by ems s / a compared to placebo in reducing the signs and symptoms resulting from uar in patients of both sexes, with age over 12 years.

the period of practical study will be conducted at the center for orofacial rehabilitation aesthetics, located in campinas-sp, where there are several beds and a large number of people served by dentists attending post-graduate, under the supervision of dr. claudio azenha. thus, patients are instructed to find the center if they experience the first signs of uars. will be included only where the top of the table has not extrapolated 48 hours. these patients will be referred to the visit of screening and early treatment (day 0 - visit 01). at a screening visit will be informed all the relevant aspects of research, enabling the patient judge the feasibility of their participation in the study. after signing the informed consent, patients will be randomized and will receive one of the treatments. this consultation will be a clinical examination where the examiner will tell the lesions and measure the size of each. besides the clinical examination there is a subjective test, in which the patient must consider the intensity of pain you're feeling at that moment, using the visual analogue scale (vas). the drug will be administered by the investigator, the patient showing the correct way of administration. after 15 minutes, the pain will be measured again, using the vas. after three days, patients should return for the 02 tour, which will be clinically evaluated and will be assessed for intensity of pain, in addition to the reporting of adverse events. the same procedures will be repeated in the return of seven days (visit 03). this visit some patients may receive high clinic. the study will be finalized after 14 days of treatment (visit 04), when patients must return to the office to the final evaluations, as will high or be exempted from the clinical study. patients who do not have improvement in time, receive replacement therapy funded by the sponsor and provided by waxen, according to the needs of each individual case, judged by expert researchers.

Eligibility criteria:
inclusion criteria: * consistency with the purposes of the study and all topics of fict; * age above 12 years; * both sexes; * diagnosis of type uar minor exclusion criteria: * use of nutritional supplements such as iron, folic acid and vitamins of the b complex; * immunocompromised; * systemic diseases (endocrine-metabolic); * rheumatic diseases; * pregnancy and lactation; * use of topical or systemic corticosteroids; * uar type major; * uar type herpetiformis; * uar over 48 hours of development; * background allergic to any components of the formula.

Keywords: aphtous bismuth procain neomycin efficacy of the association in treatment of aphtous
diagnostic accuracy of mobile phone imaging compared to conventional clinical examination for oral cancer screening

Conditions: Premalignant Lesion; Oral Cancer

Summary: the aim of study is to evaluate the sensitivity and specificity of using mobile phone photographs versus conventional clinical examination as a screening tool for early detection of oral cancer.

tele-dentistry is a method of providing oral healthcare and dental services through real-time transmission of clinical information using electronic medical records, digital imaging, photography, ict, and the internet. oral medicine is a dental specialty that uses tele-dentistry services to manage patients with systemic diseases and comorbidities. however, some oral disorders may have systemic consequences, necessitating additional diagnostic techniques and skilled doctors. issues such as lack of oral medicine specialists, inexperienced community health workers, and inadequate training for managing complex oral conditions also pose challenges. delayed diagnosis of oral cancers in underserved communities, poor patient management, high transportation costs, and lengthy waiting lists are some of the challenges faced by patients. the covid-19 pandemic has further complicated these issues, causing disruptions in educational programs and access to oral medicine services. tele-dentistry can facilitate efficient communication between patients and healthcare professionals for various purposes. there is limited research on using tele-dentistry in oral medicine, especially for results like accuracy. consequently, the present study is designed to evaluate the sensitivity and specificity of using mobile phone images versus conventional clinical examination as a screening tool for early detection of oral cancer.

Eligibility criteria:
inclusion criteria: * patients have any visible oral mucosal lesions including: 1. normal variants 2. reactive and inflammatory lesions 3. potentially malignant lesions (pml) 4. oral cancer exclusion criteria: - 1. patients unable to open their mouth properly due to trismus, pain, fibrosis or scleroderma. 2. patients unable to follow instructions such as mental disability and children below 12-year-old.

Keywords: teledentistry oral cancer screening oral potentially malignant lesions
early postoperative prevention and treatment of median sternotomy scars with botulinum toxin type a injection

Conditions: Scar

Summary: linear hypertrophic scar is a common surgical problem that can be difficult to manage, especially for the median sternotomy scar. despite high demand for the early intervention to prevent and treat surgical scars, there is yet no universal consensus on satisfactory treatment. botulinum toxin type a is a neurotoxin that has been widely and safely used in medicine for more than 30 years. it induces chemodenervation through acting on the presynaptic neuron to prevent release of acetylcholine, which leads to functional denervation of striated muscle for about 6 months after injection. the aim of this randomized controlled trial is to evaluate the efficacy of botulinum toxin type a as a prophylactic treatment in the early postoperative of median sternotomy for the purpose of preventing excess scar formation.

the goal of this study is to conduct a randomized controlled trial about using botulinum toxin type a ( bta) to prevent hypertrophic scar in median sternotomy wound. the entire median sternotomy wound was divided into the upper half and the lower half. both halves of the wound were randomized to receive treatment with either bta or 0.9% normal saline. the patient and the surgeon will be blinded to the treatment arm. the primary end point was the evaluation of upper and lower half scar using the vancouver scar scale (vss). at 6 months follow-up, two blinded dermatologists examined the patients and took photographs of the scar in the outpatient clinic of xijing hospital. scars were assessed using the vss and assigned the mean score of the two observers. at 6-month follow-up, ultrasonography to measure the scar width will be performed. at the same time, patients were asked to evaluate their overall satisfaction, using a four-point grading scale for each half the scar(1= very satisfied, 2= satisfied,3= slightly satisfied, 4= unsatisfied ).paired t-test was used to compare the vss scores, scar width and the overall satisfaction between the bta-treated group and normal saline group.

Eligibility criteria:
inclusion criteria: * patients included are older than 18 years with a median sternotomy less than 14 days. * patients are willing and able to participate in the study as an outpatient, making several visits to the study center during the treatment and follow-up periods. * patients can comply with all study requirements including concomitant medication and other treatment restrictions. * patients have good wound healing condition, without infection sign. exclusion criteria: * the exclusion criteria applied is current pregnancy or breast feeding, allergy to botulinum toxin type a, previous injection of botulinum toxin within 6 months prior to enrollment, myasthenia gravis or other neuromuscular disorder,and refusal to participate in this trial.

Keywords: botulinum toxin type a, scar
ultrasound versus fluoroscopic guided sacroiliac joint injection in patients with chronic sacroiliac joint pain

Conditions: Sacro-Iliac Spondylosis

Summary: sacroiliac joint injection in sacroiliitis

comparison of ultrasound guided and fluoroscopic guided sacroiliac joint injection

Eligibility criteria:
inclusion criteria: * clinical diagnosis of sacroiliitis. * at least 3 positive physical examination maneuvers \[faber (flexion, abduction, and external rotation), posh (posterior shear), reab (resisted abduction), fortin's finger test\], * moderate to severe pain (nrs pain score ≥ 3/10) refractory to oral anti-inflammatory. * age from 18ys to 60ys. exclusion criteria: * ages less than 18 or more than 85 years. * body mass index (bmi) above 35 kg/m2. * a diagnosis of severe anxiety or depression and other psychological disorders. * allergy to local anesthetics or steroids and pregnancy. * multiple comorbidities (renal , hepatic, cardiac). * coagulation disorder as bleeding tendency and platelet dysfunction. * contraindication for prone position or radiological exposure. * patient refuse . * pain suggestive of bilateral sacroiliac joint involvement (it would have been difficult to assess pain and disability secondary to each sij).

Keywords: sacroiliac
effect of virtual reality distraction on anxiety and pain reduction in children undergoing dental treatment

Conditions: Dental Anxiety

Summary: the aim of the study is to evaluate and compare the effect of virtual reality glasses (vr) as an audiovisual distraction method to audio distraction using music on child's dental anxiety during dental treatment.

a randomized clinical trial with parallel-group and allocation ratio (1:1). intervention group: audiovisual distraction using virtual reality glasses control group :audio distraction using music. in children aged 5-8 years who need dental extraction for primary molars. for both groups: 1. taking personal data, medical and dental history. 2. diagnosis and determination of the required treatment. 3. measuring preoperative anxiety (expressed by heart rate) using a pulse oximeter. 4. using the behavior guidance technique: intervention group: the child is introduced to the virtual reality glasses device, and was given instructions on how to use it and was allowed to choose one of previously chosen cartoons to be played during the procedure. control group: the child is introduced to the headphones and was given instructions on how to use it, and a relaxing music is played during the procedure. 5. administration of topical anesthesia. 6. administration of local anesthesia. 7. check the effectiveness of local anesthesia using dental probe. 8. extraction of the affected tooth. 9. measuring postoperative anxiety (expressed by heart rate) using the pulse oximeter. 10. evaluate the objective pain using face, legs, cry, consolabiliy scale . 11. self-reporting of subjective pain using visual analogue scale. 12. post extraction instructions are given to the patient.

Eligibility criteria:
inclusion criteria: * children aged 5-8 years. * children without any mental or systemic disorder. * children need extraction of primary molars under local anesthesia. exclusion criteria: * children with visual impairment. * children with hearing disabilities. * patients or caregivers who refuse to sign the consent.
a single-center, retrospective study to evaluate the clinical performance of artificial intelligence medical assisted diagnostic software (verisee dr) for screening of diabetic retinopathy in patients with diabetes mellitus

Conditions: Diabetic Retinopathy

Summary: this study is to evaluate the clinical performance of verisee dr for dr screening from color fundus photography images in patients with diabetes mellitus. the sensitivity and specificity of verisee dr's automated image analysis for screening the diabetes retinopathy will be determined.


Eligibility criteria:
inclusion criteria: * subjects enrolled in this study should meet all the following criteria. 1. subject with age ≥ 20 years old 2. subject with documented diagnosis of diabetes mellitus 3. subject with image taken by color fundus photography that meet the following requirement: * the resolution of image is 1024×1024 pixels or higher; * the angle view of image is 45 or 50 degree. 4. subject's image includes macula and optic nerve as judged by the ophthalmologist. exclusion criteria: * subjects will be excluded if they meet any of the following criteria. 1. the color fundus photography image previously used by verisee dr during the development process and pre-clinical test 2. the macula, optic nerve, or other part in the image of color fundus photography is unclear to determine the disease condition as judged by the ophthalmologist.
pocus screening for taa in hypertensive patients in the ed

Conditions: Thoracic Aortic Aneurysm (TAA); Aortic Dissection

Summary: the investigators are going to recruit hypertensive patients in the emergency department of prince of wales hospital. point-of-care ultrasound of the aorta and measurements of the aortic diameter will be obtained. other relevant clinical data will also be obtained for analysis. the primary outcome is the number of patients with a maximum aortic diameter of ≥ 4.5 cm and/or ≥ 50% localized enlarged diameter relative to the adjacent normal segment as indicated by pocus.

investigators trained with point-of-care ultrasound (pocus) will recruit hypertensive patients in the emergency department (ed) of prince of wales hospital. pocus will be performed using a handheld ultrasound device to visualise the aortic root, ascending aorta, aortic arch and descending aorta. measurements of the diameter will be obtained from different segments of the thoracic aorta for analysis. the definition of aortic aneurysm is a maximum aortic diameter of ≥ 4.5 cm and/or ≥ 50% localized enlarged diameter relative to the adjacent normal segment as indicated by pocus. the primary outcome is the prevalence of thoracic aortic aneurysm (taa) in hypertensive patients in the ed. the secondary outcomes include the number of patients with confirmed taa as verified by cta, bmi for all participants, the number of cta scans conducted for taa confirmation, the number of surgical interventions performed among taa patients, the icu admission rate, icu length of stay, hospital length of stay and mortality, proportion of adequate visualisation of pocus studies obtained, agreement of aortic diameter measurement between cta and pocus, and signs and symptoms of taa patients presenting to the ed. in addition, the investigators will assess the 28-day all-cause mortality and any advanced imaging done outside the ed.

Eligibility criteria:
inclusion criteria: * adult patients aged ≥ 18 years attending the ed during the study period * known history of hypertension or newly diagnosed hypertension in the ed exclusion criteria: * known history of aortic aneurysm or dissection * previous thoracic aortic interventions or endovascular stenting * patients in cardiopulmonary resuscitation * traumatic patients * patients refuse to participate the study
the strive study: development of a blood test for early detection of multiple cancer types

Conditions: Neoplasms; Cancer

Summary: grail is using high-intensity sequencing of circulating cell-free nucleic acids (cfnas) to develop blood tests to detect cancer early. the purpose of this study is to validate the ability of the pre-specified grail test to detect breast cancer and other invasive cancers, including hematologic malignancies, that will occur within one year of the first study blood draw.

detection of early stage cancer may be possible through analysis of circulating cell-free nucleic acids (cfnas) shed into the blood by tumors. grail is using high-intensity sequencing (based on broad genomic coverage and deep sequencing) of cfnas, combined with machine learning, to develop blood tests to detect cancer early. the purpose of this prospective, multi-center, observational cohort study is to validate an assay for the early detection of breast cancer and other invasive cancers, including hematologic malignancies. the study will collect blood samples from participants within 28 days of their screening mammogram. additional blood samples will also be collected for a subset of participants. for participants who receive a cancer diagnosis during the study, archival tissue samples will be collected.

Eligibility criteria:
inclusion criteria: 1. women undergoing mammography for screening indications or have an appointment for screening mammography. 2. participant provides informed consent and expresses understanding of the protocol and its requirements, risks, and discomforts. exclusion criteria: none.

Keywords: cancer screening high-throughput nucleotide sequencing deep sequencing circulating cell-free tumor dna
registry for vascular anomalies associated with coagulopathy

Conditions: Multifocal Lymphangioendotheliomatosis With Thrombocytopenia; Cutaneovisceral Angiomatosis With Thrombocytopenia; Vascular Anomaly With Thrombocytopenia; Hemangiomas

Summary: purpose the purpose of this study is to learn more about multifocal lymphangioendotheliomatosis with thrombocytopenia (mlt). mlt is a rare vascular disorder characterized by multiple congenital skin and visceral lesions, profound thrombocytopenia, and gastrointestinal bleeding. the skin lesions may appear red, brown or blue, often misdiagnosed as hemangiomas. the gastrointestinal tract, liver, and lungs are the most common internal organs involved. the severe thrombocytopenia (low platelets) is believed to be the result of platelet trapping within the skin and visceral vascular lesions. severe and chronic gastrointestinal bleeding is common during infancy and early childhood. although a relatively newly described entity, mlt was likely previously reported as hemangiomas, blue rubber bleb nevus syndrome, diffuse hemangiomatosis, kasabach-merritt phenomenon, and hereditary hemorrhagic telangiectasia. the term cutaneovisceral angiomatosis with thrombocytopenia is also a term used for this same disease. this study is a longitudinal cohort study of mlt to collect detailed clinical data on the distribution of disease, disease severity, and complications. this data will be used to create diagnostic criteria and an evaluation protocol for infants with this disease

after informed consent is obtained a detailed question will be mailed to participating patients and families. this questionnaire will also be available electronically through an educational website. data collected will include photographs of skin lesions, video images of gastrointestinal lesions, demographic data, clinical information, therapeutic interventions, glass slides of tissue biopsies, and collection of dna. enrollment will be patient family driven and modeled after several successful registries of rare diseases.

Eligibility criteria:
inclusion criteria: * subjects with a vascular anomaly with coagulopathy exclusion criteria: * subjects without a vascular anomaly with coagulopathy

Keywords: multifocal lymphangioendoltheliomatosis with thrombocytopenia cutaneovisceral angiomatosis with thrombocytopenia thrombocytopenia hemangiomas hemangiomatosis lymphatic malformation kasabach-merritt blue-rubber bleb nevus angiomatosis
sash: sodium accumulation study in haemodialysis

Conditions: Haemodialysis; End Stage Renal Disease on Dialysis

Summary: haemodialysis (hd) sustains life in patients with end-stage kidney disease (eskd) but is associated with a marked increase in incidence of cardiovascular disease (cvd) and high annual mortality rates. the pathogenesis of cvd in patients on hd is multifactorial and complex but hypertension is thought to be a major contributing factor. sodium balance is normally regulated by the kidneys in health but has to be achieved by sodium removal during hd for those with eskd. recent evidence suggests that accumulation of sodium in the skin and / or muscle may be a critical factor impacting the development of hypertension and cvd in patients with eskd and non-invasive methods are therefore required to study tissue sodium accumulation in this context. this study aims to determine the change in skin and muscle sodium content in patients undergoing haemodialysis. participants will have a single haemodialysis session, and undergo two mri scans (one prior to and one following dialysis).

it has been proposed that tissue sodium accumulation in skin and/or muscle is a key factor in hypertension. 23na mri allows the assessment of skin and muscle sodium storage and will therefore be a valuable tool in elucidating the role of tissue sodium accumulation in the pathogenesis of salt-sensitive hypertension and cardiovascular morbidity and mortality. moreover, if haemodialysis in patients with end-stage kidney disease (eskd) results in changes in tissue sodium, the development of 23na skin and muscle measures would allow for a method to correlate skin tissue sodium content with detailed cardiovascular and functional assessments. participants will have a single haemodialysis session, and undergo two mri scans (one prior to and one following dialysis), in conjunction with clinical data collection (eg. blood samples, bioimpedance analysis, skin autoflorescence).

Eligibility criteria:
inclusion criteria: * age 50-75 years inclusive * male patients with ckd stage 5 receiving chronic haemodialysis * patient has been dialysis dependent for at least 3 months * must be able to follow simple instruction in english (on safety ground for mri scans) and be able to understand the nature and requirements of the study exclusion criteria: * active infection or malignancy * amputee * pregnancy * contraindication to mri scanning including claustrophobia, pacemaker, metallic implants etc * unable or unwilling to provide informed consent * medical conditions or overall physical frailty precludes scan session in opinion of investigator * any condition which could interfere with the patient's ability to comply with the study
clinical study on nanocrystalline megestrol acetate for appetite improvement and weight gain in pre-cachexia and cachexia stages key terminology analysis

Conditions: Metastatic (Stage IV) Non-squamous Non-small Cell Lung Cancer (Nsq-NSCLC) With Driver Gene Negativity; Untreated With Systemic Therapy

Summary: the purpose of this study is to evaluate the efficacy and safety of nanocrystalline medroxyprogesterone acetate for improving appetite and weight gain patients with non-small cell lung cancer (nsclc) and cachexia and pre-cachexia. the enrolled patients were those with advanced nsclc who had not received therapy, negative for driver genes and ineligible for curative treatment, and were planned to receive pd-1 inhibitors in combination with platinum-based chemotherapy.


Eligibility criteria:
inclusion criteria: * ≥18 years at the time of enrollment. * eastern cooperative oncology group (ecog) performance status score of 0-2. * life expectancy ≥6 months. * histologically or cytologically confirmed metastatic (stage iv) driver gene-negative non-squamous non-small cell lung cancer (nsclc) that is unresectable and not amenable to curative therapy * subjects with no prior systemic chemotherapy for metastatic non-small cell lung cancer (nsclc). exclusion criteria: * presence of any gastrointestinal absorption-impairing conditions (e.g., dysphagia, malabsorption, prior gastrectomy, or uncontrolled vomiting); current use of tube feeding/parenteral nutrition; or existence of anorexia nervosa, psychiatric disorder-induced anorexia, or pain-related feeding intolerance. * driver gene-positive nsclc or histologically/cytologically confirmed squamous cell-dominant nsclc. * patients with cushing's syndrome, adrenal/pituitary insufficiency; poorly controlled diabetes mellitus. * concurrent enrollment in another clinical trial, unless it is an observational/non-interventional study or the follow-up phase of an interventional trial.